|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K2317/33 | (2013.01) |
| A61P 11/06 | (2006.01) | ||
| C07K 16/18 | (2006.01) | ||
| C07K2317/34 | (2013.01) | ||
| A61K 39/00 | (2006.01) | ||
| C07K2317/76 | (2013.01) | ||
| C07K2317/92 | (2013.01) | ||
| A61K2039/505 | (2013.01) | ||
| C07K 16/18 | (2013.01) | ||
| A61P 1/04 | (2018.01) | ||
| A61P 11/00 | (2018.01) | ||
| A61P 11/06 | (2018.01) | ||
| A61P 13/12 | (2018.01) | ||
| A61P 17/00 | (2018.01) | ||
| A61P 21/00 | (2018.01) | ||
| A61P 21/04 | (2018.01) | ||
| A61P 25/00 | (2018.01) | ||
| A61P 25/14 | (2018.01) | ||
| A61P 25/16 | (2018.01) | ||
| A61P 25/28 | (2018.01) | ||
| A61P 27/02 | (2018.01) | ||
| A61P 27/06 | (2018.01) | ||
| A61P 29/00 | (2018.01) | ||
| A61P 3/00 | (2018.01) | ||
| A61P 3/04 | (2018.01) | ||
| A61P 37/02 | (2018.01) | ||
| A61P 37/06 | (2018.01) | ||
| A61P 7/00 | (2018.01) | ||
| A61P 7/06 | (2018.01) | ||
| A61P 9/10 | (2018.01) | ||
| A61P 3/10 | (2018.01) |
| (11) | Number of the document | 3019240 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14822371.2 |
| Date of filing the European patent application | 2014-07-09 | |
| (97) | Date of publication of the European application | 2016-05-18 |
| (45) | Date of publication and mention of the grant of the patent | 2024-03-13 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2014/046042 |
| Date | 2014-07-09 |
| (87) | Number | WO 2015/006504 |
| Date | 2015-01-15 |
| (30) | Number | Date | Country code |
| 201361844369 P | 2013-07-09 | US | |
| 201361871813 P | 2013-08-29 | US |
| (72) |
ROSENTHAL, Arnon , US
LEVITEN, Michael , US
|
| (73) |
Annexon, Inc. ,
1400 Sierra Point Parkway
Building C, 2nd Floor, Brisbane, CA 94005,
US
|
| (54) | ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF |
| ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF |